Literature DB >> 19650798

Infusion requirements and reversibility of rocuronium at the corrugator supercilii and adductor pollicis muscles.

T Suzuki1, H Mizutani, E Miyake, N Fukano, S Saeki, S Ogawa.   

Abstract

BACKGROUND: The aim of this study is to compare the infusion rates required to maintain a constant neuromuscular block and the reversibility of rocuronium at the corrugator supercilii muscle (CSM) and the adductor pollicis muscle (APM).
METHODS: We randomly allocated 30 female patients into two groups of 15 patients each to monitor neuromuscular block at either the CSM or the APM. After induction of anaesthesia and laryngeal mask insertion, contraction of the CSM to the facial nerve stimulation or that of the APM to the ulnar nerve stimulation was quantified using an acceleromyograph during 1.0-1.5% end-tidal sevoflurane anaesthesia. All the patients received a bolus of 1 mg/kg rocuronium. When the first twitch (T1) of train-of-four (TOF) recovered to 10% of the control, rocuronium infusion was commenced and maintained at T1 of 10% of the control at the CSM or APM for 120 min. Immediately after rocuronium infusion was discontinued, the time required for 0.04 mg/kg neostigmine-facilitated recovery to a TOF ratio of 0.9 was recorded.
RESULTS: Rocuronium infusion dose after a lapse of 120 min was significantly larger in the CSM than in the APM [7.1 (2.3) vs. 4.7 (2.6) microg/kg/min; P=0.001]. The time for facilitated recovery was shorter in the CSM than in the APM [11.4 (3.8) vs. 16.2 (6.0) min; P=0.016].
CONCLUSION: A larger rocuronium infusion dose was required to maintain a constant neuromuscular block at the CSM. Neostigmine-mediated reversal was faster at the CSM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650798     DOI: 10.1111/j.1399-6576.2009.02073.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

1.  Effectiveness of the timing principle with high-dose rocuronium during rapid sequence induction with lidocaine, remifentanil and propofol.

Authors:  Takahiro Suzuki; Mayu Aono; Naoko Fukano; Makiko Kobayashi; Shigeru Saeki; Setsuro Ogawa
Journal:  J Anesth       Date:  2010-02-26       Impact factor: 2.078

2.  Effect of a Cognitive Aid on Reducing Sugammadex Use and Associated Costs: A Time Series Analysis.

Authors:  Dan M Drzymalski; Roman Schumann; Frank J Massaro; Agnieszka Trzcinka; Ruben J Azocar
Journal:  Anesthesiology       Date:  2019-11       Impact factor: 7.892

3.  Efficiency of the TOF-Cuff™ for the evaluation of rocuronium-induced neuromuscular block and its reversal with sugammadex: a comparative study vs. acceleromyography.

Authors:  Yasuhito Kameyama; Shunichi Takagi; Katsuhisa Seto; Ichie Kajiwara; Miori Goto; Osamu Kitajima; Takahiro Suzuki
Journal:  J Anesth       Date:  2018-11-24       Impact factor: 2.078

4.  Sensitivity to rocuronium-induced neuromuscular block and reversibility with sugammadex in a patient with myotonic dystrophy.

Authors:  Akihiro Kashiwai; Takahiro Suzuki; Setsuro Ogawa
Journal:  Case Rep Anesthesiol       Date:  2012-04-09

Review 5.  Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives.

Authors:  Michele Carron; Francesco Bertoncello; Giovanna Ieppariello
Journal:  Clin Interv Aging       Date:  2017-12-22       Impact factor: 4.458

6.  Prolonged onset and duration of action of rocuronium after accidental subcutaneous injection in a patient with chronic renal failure-a case report.

Authors:  Akira Doshu-Kajiura; Junko Suzuki; Takahiro Suzuki
Journal:  JA Clin Rep       Date:  2021-02-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.